TMCnet - World's Largest Communications and Technology Community



Research and Markets: Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
[April 28, 2014]

Research and Markets: Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Vical Incorporated
  • Sanofi
  • GenVec, Inc.
  • Astellas Pharma Inc.
  • CEL-SCI Corporation
  • Mymetics Corporation
  • NovaBay Pharmaceuticals, Inc.
  • Nutra Pharma Corporation
  • Peregrine Pharmaceuticals, Inc.
  • Oryzon Genomics S.A.
  • Colby Pharmaceutical Company
  • Osel Inc.
  • AlphaVax, Inc.
  • Romark Laboratories, L.C.
  • Chimerix, Inc.
  • NanoBio Corporation
  • Immunovaccine, Inc.
  • Immune Design Corp.
  • Seek
  • Adamis Pharmaceuticals Corporation
  • Vaxart, Inc.
  • Genocea Biosciences, Inc.
  • Profectus BioSciences, Inc.
  • 3-V Biosciences, Inc.
  • Spider Biotech S.r.l.
  • Kala Pharmaceuticals, Inc.
  • Coridon Pty Ltd
  • Sanofi Pasteur SA
  • Humabs BioMed SA
  • BioApex, s.r.o.

Drug Profiles

  • amenamevir
  • tenofovir
  • RPI-78M
  • RPI-MN
  • HSV-2 Vaccine
  • CEL-1000
  • HSV Vaccine
  • HSV-2 Vaccine
  • C-31-G
  • MucoCept Platform
  • HSV-2 Px
  • NVC-727
  • JVRS-100 + Herpes Simplex Virus-2 Vaccine
  • Drug for Herpes Simplex
  • PGN-632
  • GV-2207
  • MB-66
  • Small Molecule Targeting Fatty Acid Synthase for Infectious Disease
  • BA-368
  • HSV-2 Vaccine
  • RKP-00156
  • CEL-1000
  • MAb hu2c
  • HSV Vaccine
  • Drug For Herpes Simplex Virus
  • Subunit Vaccine for Herpes Simplex Virus 2
  • Small Molecules for Viral Infections
  • Small Molecules for Bacterial and Viral Infections

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy